Phase 1-2 Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2024.12.027 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Juhi M Purswani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, New York University Langone Health and Perlmutter Cancer Center, New York, New York. Electronic address: juhi.pursw…. Hauptthemen laut MEDLINE: Radiotherapy, Intensity-Modulated, Breast Neoplasms, Radiation Dose Hypofractionation, Lymphatic Irradiation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: AstraZeneca, Bayer, New York University Grossman School of Medicine.
Abstract (Originalsprache)
PURPOSE: In patients with breast cancer, prone radiation therapy (RT) has been shown to reduce heart and lung dose. Though prone positioning is routinely used for whole breast RT, its use when treating the regional lymph nodes is not widespread. METHODS AND MATERIALS: In this phase 1/2 trial for stage IB-IIA breast cancer treated with lumpectomy or mastectomy, patients received 40.5 Gy in 15 fractions to the breast or chest wall and regional lymph nodes with an integrated tumor bed boost for lumpectomy patients. Primary endpoints were grade >2 acute toxicity and dosimetric feasibility. Secondary endpoints were the incidence of resimulation to improve dosimetry and late toxicity. Exploratory endpoints were local recurrence, disease-free survival, distant recurrence-free survival, and overall survival. RESULTS: From 2009 to 2016, 97 patients were enrolled (68% lumpectomy and 32% mastectomy), among which 92 were treated in the prone position. Five patients were resimulated and treated supine. Among the prone-treated patients, there were no acute toxicities greater than grade 2. A total of 92%, 98%, and 89% met a planning target volume tumor V48 Gy ≥98%, breast V40.5 Gy ≥95%, and nodal V38.5 Gy ≥95%, respectively. All met the heart V5 Gy
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, New York University Langone Health and Perlmutter Cancer Center, New York, New York. Electronic address: juhi.purswani@nyumc.org.
- Department of Radiation Oncology, New York University Langone Health and Perlmutter Cancer Center, New York, New York.
- Department of Population Health, Division of Biostatistics, New York University Langone Health and Perlmutter Cancer Center, New York, New York.
- St. Jude Children's Research Hospital, Memphis, Tennessee.
- Department of Radiation Oncology, Cornell University Medical Center, New York, New York.
Förderung
- AstraZeneca
- Bayer
- New York University Grossman School of Medicine
Zitieren
APA
Purswani, J. M., Maisonet, O., Xiao, J., Teruel, J. R., Hitchen, C., Li, X., Goldberg, J. D., Perez, C. A., Formenti, S. C., & Gerber, N. K. (2025). Phase 1-2 Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.12.027
Vancouver
Purswani JM, Maisonet O, Xiao J, Teruel JR, Hitchen C, Li X, et al. Phase 1-2 Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2024.12.027
BibTeX
@article{Purswani2025,
author = {Purswani, Juhi M and Maisonet, Olivier and Xiao, Julie and Teruel, Jose R and Hitchen, Christine and Li, Xiaochun and Goldberg, Judith D and Perez, Carmen A and Formenti, Silvia C and Gerber, Naamit K},
title = {Phase 1-2 Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2024.12.027}
}
EUVIMED